Edgewise Therapeutics shares tumbled more than 20% Wednesday after the developmental drug company issued the results of its latest clinical trial.

In this article, we are going to take a look at where Edgewise Therapeutics, Inc. (NASDAQ:EWTX) stands against other stocks ...

Avoid the stress of overpaying for a stock or missing an opportunity by using the right tools and insights to evaluate ...

We recently published a list of 10 Unstoppable Stocks That Could Double Your Money. In this article, we are going to take a ...

Piper Sandler reaffirmed their overweight rating on shares of Edgewise Therapeutics (NASDAQ:EWTX – Free Report) in a research ...

Discover growth opportunities with Edgewise Therapeutics, Inc. in the hypertrophic cardiomyopathy market. Click for my EWTX stock update.

Across the study, two patients experienced “serious adverse events of atrial fibrillation (AF) requiring cardioversion,” Edgewise said. The rates of AF—a term for irregular heart rhythm—were in the ...

Piper Sandler analyst Yasmeen Rahimi remains bullish on Edgewise Therapeutics (EWTX) and maintains an Overweight rating and $51 price target on ...

Edgewise Therapeutics (EWTX) announced top-line data of EDG-7500 from the Phase 2 CIRRUS-HCM four-week trial in participants with obstructive ...

BOULDER, Colo., April 2, 2025 /PRNewswire/ -- Edgewise Therapeutics, Inc. (NASDAQ: EWTX), a leading muscle disease biopharmaceutical company, today announced the pricing of an underwritten ...

Edgewise Therapeutics (NASDAQ:EWTX – Get Free Report) had its price target lowered by research analysts at Royal Bank of ...

In this article, we are going to take a look at where Edgewise Therapeutics, Inc. (NASDAQ:EWTX) stands against other unstoppable stocks that could double your money. Generating significant returns ...